Leveraging human genomics to advance ASIC1a-targeted therapeutics for ischemic diseases

Campus Plus are pleased to announce our latest award launch under the National Industry PhD Program.

This partnership brings together the world-class drug development and clinical trial capabilities of Infensa Bioscience and the genomics and statistical genetics expertise of The University of Queensland to explore new ways to harness human genetics for better treatments for ischemic diseases.

The project, “Leveraging human genomics to advance ASIC1a-targeted therapeutics for ischemic diseases”, will use genetic approaches to establish ASIC1a’s role in human health and disease, identify new therapeutic opportunities for ASIC1a inhibitors, and detect potential safety considerations for clinical development. The goal is to de-risk clinical development and accelerate translation of ASIC1a inhibitors to treat conditions that comprise the leading causes of morbidity and mortality globally.

The research will be conducted by PhD candidate Shaine Bao with academic support from Professor Nathan Palpant from The University of Queensland Institute of Molecular Bioscience, and the industry mentorship of Michael Ankersen PhD MBA from Infensa Bioscience.

Congratulations to all involved, and all the best for this research journey! Campus Plus are here to support you.